NCT04720196

Brief Summary

Vasculitic neuropathy (VN) results from inflammation and destruction of the walls of predominantly small vessels with subsequent ischemic damage of peripheral nerves. VN is painful in vast majority of patients and the pain is intractable with pharmacotherapy in about 40% of cases. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity and is regarded as one of alternative methods to alleviate pain associated with various kind of neuropathies. The purpose of this study is to compare the effectiveness of analgesic effect of rTMS in vasculitic neuropathy with sham stimulation.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 16, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 22, 2021

Completed
3 days until next milestone

Study Start

First participant enrolled

January 25, 2021

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2023

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 21, 2023

Completed
Last Updated

October 2, 2023

Status Verified

September 1, 2023

Enrollment Period

2.7 years

First QC Date

January 16, 2021

Last Update Submit

September 28, 2023

Conditions

Keywords

vasculitisneuropathypaintranscranial magnetic stimulationanalgesic effect

Outcome Measures

Primary Outcomes (4)

  • Numeric Pain Severity Scale after rTMS

    Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken after finishing rTMS.

    Before rTMS, immediately after (on same day) finishing rTMS.

  • Numeric Pain Severity Scale First Follow Up

    Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken two weeks after finishing rTMS.

    Before rTMS, two weeks after finishing rTMS

  • Numeric Pain Severity Scale Second Follow Up

    Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken four weeks after finishing rTMS.

    Before rTMS, four weeks after finishing rTMS

  • Visual Analog Scale of Pain Severity

    An analog scale of the length of 100 milimeter. Total score of 100, with higher scores representing more severe pain. Change through the study.

    Through study completion, an average of 10 weeks

Secondary Outcomes (33)

  • Hospital Anxiety and Depression Scale after rTMS

    Before rTMS, immediately after (on same day) finishing rTMS.

  • Hospital Anxiety and Depression Scale First Follow Up

    Before rTMS, two weeks after finishing rTMS

  • Hospital Anxiety and Depression Scale Second Follow Up

    Before rTMS, four weeks after finishing rTMS

  • 36-Item Short Form Health Survey after rTMS

    Before rTMS, immediately after (on same day) finishing rTMS.

  • 36-Item Short Form Health Survey First Follow Up

    Before rTMS, two weeks after finishing rTMS

  • +28 more secondary outcomes

Study Arms (2)

Active repetitive transcranial magnetic stimulation

EXPERIMENTAL

10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 5 daily sessions (on consecutive week days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.

Device: Active repetitive transcranial magnetic stimulation

Sham repetitive transcranial magnetic stimulation

SHAM COMPARATOR

Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.

Device: Sham repetitive transcranial magnetic stimulation

Interventions

High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.

Active repetitive transcranial magnetic stimulation

Sham stimulation to mimic the high frequency rTMS over the primary motor area.

Sham repetitive transcranial magnetic stimulation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of vasculitic neuropathy
  • Neuropathic pain of constant severity since not less than a month and requiring use of analgesics more than once a week

You may not qualify if:

  • Severe depression
  • Personality disorders and other psychiatric conditions, which could disturb the participation in the study
  • Cognitive deficits, which could disturb the participation in the study
  • Contraindications for rTMS as listed by the Guidelines of the International Federation of Clinical Neurophysiology (Rossi et al. 2009) i.e. seizure in the past, epilepsy, presence of magnetic material in the reach of magnetic field, pregnancy, likelihood to get pregnant, intracranial electrodes, cardiac pacemaker or intracardiac lines, frequent syncopes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jagiellonian University Medical College, Department of Neurology

Krakow, 31503, Poland

Location

Related Publications (1)

  • Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14.

    PMID: 19833552BACKGROUND

MeSH Terms

Conditions

VasculitisPain

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Justyna Brączyk, MS

    Jagiellonian University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Sham stimulation will be provided by holding the stimulating coil perpendicularly to the scalp, which assures similar impression as during active stimulation but prevents significant magnetic field to reach the brain tissue.
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Patients will be randomly assigned to active and then sham stimulation or to sham and then active stimulation.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 16, 2021

First Posted

January 22, 2021

Study Start

January 25, 2021

Primary Completion

September 20, 2023

Study Completion

September 21, 2023

Last Updated

October 2, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will share

After completing the study, the age and gender of participants as well as the scores and results of all outcome measurements made at baseline, after rTMS, at the first and at the second follow up will be made available to other researchers on request.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
The data will become available after the study results will be published.
Access Criteria
On request send by e-mail: jakub.antczak@uj.edu.pl

Locations